HepaTx
Palo Alto
About HepaTx
HepaTx is developing regenerative medicine solutions to address the need for better therapies for life-threatening liver diseases. The technology invented at Stanford University enables efficient hepatocyte production for therapeutic purposes. Its therapeutics can replace lost liver function to treat those with end-stage of liver disease, potentially saving the cost and morbidity of whole organ transplant.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.2M
- Funding stage: Seed
- Last round: Grant (May 2025)
- Website: hepatx.com
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hepatx-65332 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.